**Chapter 4**

*Advances in Hematologic Malignancies*

[174] Maude SL, Pulsipher MA, Boyer MW. Efficacy and safety of CTL019 in the first US phase II multicentre trial in pediatric relapsed/ refractory acute leukemia: Results of an interim analysis. Blood. 2016;**128**:2801

of patients treated for relapsed or refractory acute lymphoblastic leukemia: A therapeutic advances in childhood leukemia consortium study. Journal of Clinical Oncology.

2010;**28**:648-654

[175] Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, et al. Outcome

[176] Maude SL, Laetsch TW, Buechner S,

Rives S, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine. 2018;**378**:439-448

[177] Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptormodified T cells for acute lymphoid leukemia. The New England Journal of Medicine. 2013;**368**(16):1509-1518

[178] Hunault-Berger M,

2011;**96**(2):245-252

2012;**34**(3):208-216

Leguay T, Thomas X, Legrand O,

study of pegylated liposomal doxorubicin versus continuous-

Huguet F, Bonmati C, et al. A randomized

infusion doxorubicin in elderly patients with acute lymphoblastic leukemia. GRALL-SA1 study. Haematologica.

[179] Quarello P, Berger M, Rivetti E, Galletto C, Masetti R, et al. FLAGliposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients. Journal of Pediatric Hematology/Oncology.

[180] ClinicalTrials.gov. A Pilot Study of Vincristine Sulphate Liposome Injection

in Combination with UKALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia. Identifier: NCT02879643

**56**
